Scandinavia Pharmaceuticals Market Summary, Competitive Analysis and Forecast to 2027
![](/report_cover/4228/scandinavia-pharmaceuticals-market-summary-competitive-analysis-n-forecast-to-2027_en.gif)
Scandinavia Pharmaceuticals Market Summary, Competitive Analysis and Forecast to 2027
Summary
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2017-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
Summary
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2017-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The Scandinavian pharmaceuticals market had total revenues of $17.1 billion in 2022, representing a compound annual growth rate (CAGR) of 3.4% between 2017 and 2022.
- 0
- Sweden acquired a 38% share of the Scandinavian pharmaceuticals market in 2022. The Nordics are a significant hub for pharmaceutical innovation and production, with Finland having one of Europe's fastest-aging populations. With over 23% of people aged 65 or over, the region has a high life expectancy at birth. Lifestyle-related diseases like diabetes and obesity are driving growth in the pharmaceutical markets, particularly cardiovascular ones.
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the pharmaceuticals market in Scandinavia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts by both value and volume
- What was the size of the Scandinavia pharmaceuticals market by value in 2022?
- What will be the size of the Scandinavia pharmaceuticals market in 2027?
- What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?
- How has the market performed over the last five years?
- What are the main segments that make up Scandinavia's pharmaceuticals market?
1 EXECUTIVE SUMMARY
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market rivalry
1.5. Competitive landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What strategies do leading players follow?
7.3. What are the most recent market developments?
8 COMPANY PROFILES
8.1. Novartis AG
8.2. Sanofi SA
8.3. Pfizer Inc.
8.4. F. Hoffmann-La Roche Ltd
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market rivalry
1.5. Competitive landscape
2 MARKET OVERVIEW
2.1. Market definition
2.2. Market analysis
3 MARKET DATA
3.1. Market value
4 MARKET SEGMENTATION
4.1. Geography segmentation
5 MARKET OUTLOOK
5.1. Market value forecast
6 FIVE FORCES ANALYSIS
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 COMPETITIVE LANDSCAPE
7.1. Who are the leading players?
7.2. What strategies do leading players follow?
7.3. What are the most recent market developments?
8 COMPANY PROFILES
8.1. Novartis AG
8.2. Sanofi SA
8.3. Pfizer Inc.
8.4. F. Hoffmann-La Roche Ltd
9 MACROECONOMIC INDICATORS
9.1. Country data
10 APPENDIX
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
LIST OF TABLES
Table 1: Scandinavia pharmaceuticals market value: $ billion, 2017-22
Table 2: Scandinavia pharmaceuticals market geography segmentation: $ billion, 2022
Table 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2022-27
Table 4: Novartis AG: key facts
Table 5: Novartis AG: Annual Financial Ratios
Table 6: Novartis AG: Key Employees
Table 7: Novartis AG: Key Employees Continued
Table 8: Sanofi SA: key facts
Table 9: Sanofi SA: Annual Financial Ratios
Table 10: Sanofi SA: Key Employees
Table 11: Sanofi SA: Key Employees Continued
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: F. Hoffmann-La Roche Ltd: key facts
Table 17: F. Hoffmann-La Roche Ltd: Annual Financial Ratios
Table 18: F. Hoffmann-La Roche Ltd: Key Employees
Table 19: Scandinavia exchange rate, 2018-22
Table 1: Scandinavia pharmaceuticals market value: $ billion, 2017-22
Table 2: Scandinavia pharmaceuticals market geography segmentation: $ billion, 2022
Table 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2022-27
Table 4: Novartis AG: key facts
Table 5: Novartis AG: Annual Financial Ratios
Table 6: Novartis AG: Key Employees
Table 7: Novartis AG: Key Employees Continued
Table 8: Sanofi SA: key facts
Table 9: Sanofi SA: Annual Financial Ratios
Table 10: Sanofi SA: Key Employees
Table 11: Sanofi SA: Key Employees Continued
Table 12: Pfizer Inc.: key facts
Table 13: Pfizer Inc.: Annual Financial Ratios
Table 14: Pfizer Inc.: Key Employees
Table 15: Pfizer Inc.: Key Employees Continued
Table 16: F. Hoffmann-La Roche Ltd: key facts
Table 17: F. Hoffmann-La Roche Ltd: Annual Financial Ratios
Table 18: F. Hoffmann-La Roche Ltd: Key Employees
Table 19: Scandinavia exchange rate, 2018-22
LIST OF FIGURES
Figure 1: Scandinavia pharmaceuticals market value: $ billion, 2017-22
Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2022-27
Figure 4: Forces driving competition in the pharmaceuticals market in Scandinavia, 2022
Figure 5: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2022
Figure 6: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2022
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2022
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2022
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2022
Figure 1: Scandinavia pharmaceuticals market value: $ billion, 2017-22
Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 3: Scandinavia pharmaceuticals market value forecast: $ billion, 2022-27
Figure 4: Forces driving competition in the pharmaceuticals market in Scandinavia, 2022
Figure 5: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2022
Figure 6: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2022
Figure 7: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2022
Figure 8: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2022
Figure 9: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2022